CYTK Quote, Financials, Valuation and Earnings

Fortrea Holdings, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of -2.27%. Cytokinetics, Inc.'s return on equity of -- beat Fortrea Holdings, Inc.'s return on equity of -104.76%.

Cytokinetics, Inc. has a consensus price target of $88.22, signalling upside risk potential of 41.13%. On the other hand Fortrea Holdings, Inc. has an analysts' consensus of $15.16 which suggests that it could fall by -12.8%. Given that Cytokinetics, Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe Cytokinetics, Inc. is more attractive than Fortrea Holdings, Inc..

Cytokinetics, Inc. has a beta of 0.553, which suggesting that the stock is 44.718% less volatile than S&P 500. In comparison Fortrea Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortrea Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Fortrea Holdings, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Fortrea Holdings, Inc. quarterly revenues of $701.3M. Cytokinetics, Inc.'s net income of -$306.2M is lower than Fortrea Holdings, Inc.'s net income of -$15.9M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Fortrea Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 85.30x versus 0.57x for Fortrea Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Jasper Therapeutics, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of --. Cytokinetics, Inc.'s return on equity of -- beat Jasper Therapeutics, Inc.'s return on equity of -204.39%.

Cytokinetics, Inc. has a consensus price target of $88.22, signalling upside risk potential of 41.13%. On the other hand Jasper Therapeutics, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 716.78%. Given that Jasper Therapeutics, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe Jasper Therapeutics, Inc. is more attractive than Cytokinetics, Inc..

Cytokinetics, Inc. has a beta of 0.553, which suggesting that the stock is 44.718% less volatile than S&P 500. In comparison Jasper Therapeutics, Inc. has a beta of 2.688, suggesting its more volatile than the S&P 500 by 168.779%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jasper Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Jasper Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are larger than Jasper Therapeutics, Inc. quarterly revenues of --. Cytokinetics, Inc.'s net income of -$306.2M is lower than Jasper Therapeutics, Inc.'s net income of -$18.7M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Jasper Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 85.30x versus -- for Jasper Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lifecore Biomedical, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of -32.12%. Cytokinetics, Inc.'s return on equity of -- beat Lifecore Biomedical, Inc.'s return on equity of -70.33%.

Cytokinetics, Inc. has a consensus price target of $88.22, signalling upside risk potential of 41.13%. On the other hand Lifecore Biomedical, Inc. has an analysts' consensus of $9.25 which suggests that it could grow by 22.36%. Given that Cytokinetics, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Cytokinetics, Inc. is more attractive than Lifecore Biomedical, Inc..

Cytokinetics, Inc. has a beta of 0.553, which suggesting that the stock is 44.718% less volatile than S&P 500. In comparison Lifecore Biomedical, Inc. has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.877%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifecore Biomedical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Lifecore Biomedical, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Lifecore Biomedical, Inc. quarterly revenues of $31.1M. Cytokinetics, Inc.'s net income of -$306.2M is lower than Lifecore Biomedical, Inc.'s net income of -$10M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Lifecore Biomedical, Inc.'s PE ratio is 133.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 85.30x versus 2.04x for Lifecore Biomedical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -15814.98% compared to Cytokinetics, Inc.'s net margin of 0.69%. Cytokinetics, Inc.'s return on equity of -- beat Molina Healthcare, Inc.'s return on equity of 19.74%.

Cytokinetics, Inc. has a consensus price target of $88.22, signalling upside risk potential of 41.13%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $184.13 which suggests that it could grow by 1.45%. Given that Cytokinetics, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Cytokinetics, Inc. is more attractive than Molina Healthcare, Inc..

Cytokinetics, Inc. has a beta of 0.553, which suggesting that the stock is 44.718% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.491, suggesting its less volatile than the S&P 500 by 50.861%.

Cytokinetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Cytokinetics, Inc. quarterly revenues are $1.9M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.5B. Cytokinetics, Inc.'s net income of -$306.2M is lower than Molina Healthcare, Inc.'s net income of $79M. Notably, Cytokinetics, Inc.'s price-to-earnings ratio is -- while Molina Healthcare, Inc.'s PE ratio is 11.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics, Inc. is 85.30x versus 0.22x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.